ClinConnect ClinConnect Logo
Search / Trial NCT06873698

Pilot Neurobehavioral Therapy for Functional Neurological Disorder

Launched by RHODE ISLAND HOSPITAL · Mar 7, 2025

Trial Information

Current as of April 30, 2025

Recruiting

Keywords

M Fnd Conversion Disorder Functional Neurologic Disorder Neurobehavioral Therapy Fnd Psychogenic Movement Disorder Psychotherapy Motor Functional Neurological Disorder Functional Motor Disorder

ClinConnect Summary

This clinical trial is researching a treatment called Neurobehavioral Therapy (NBT) for people diagnosed with Motor Functional Neurological Disorder (mFND). The goal is to see if NBT can help improve the quality of life and reduce symptoms for those with this condition. The study will involve 40 participants, who will be divided into two groups: one group will receive NBT over 12 to 18 weeks, while the other group will continue with their standard medical care. Throughout the study, all participants will attend five clinic visits over one year to answer questions and complete surveys about their health and symptoms.

To be eligible for this trial, participants should be between 18 and 70 years old and have been diagnosed with mFND, experiencing at least one symptom in the past year. However, individuals with certain conditions, such as severe mental health issues, serious illnesses, or those currently engaged in other treatments for mFND, will not be able to participate. This study aims to gather important information that could guide future research and help improve treatments for mFND.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Individuals diagnosed with Motor Functional Neurological Disorder (mFND)
  • Individuals aged 18-70 years
  • At least 1 mFND symptom during the year prior to enrollment
  • Exclusion Criteria:
  • Current or past year self-injurious behavior
  • Current suicidality (PHQ-9 question 9 rated as 1 or above)
  • Current or past year psychosis
  • Pending litigation or current application for long term disability
  • Active substance or alcohol use disorders (dependence), at the discretion of the investigator if they preclude participation in the study
  • Serious illness requiring systemic treatment or hospitalization; the participant either completes therapy or is clinically stable on therapy, for at least 30 days prior to study entry
  • Inability to fill out the self-report surveys
  • Inability or unwillingness to participate in NBT and assigned homework
  • Currently enrolled in NBT aimed at mFND

About Rhode Island Hospital

Rhode Island Hospital, a leading academic medical center and a key component of the Lifespan health system, is committed to advancing medical research and improving patient care through innovative clinical trials. As a principal teaching hospital for The Warren Alpert Medical School of Brown University, it integrates cutting-edge research with high-quality clinical services. The hospital's extensive clinical trial program spans various fields, including oncology, cardiology, neurology, and more, aiming to enhance treatment options and patient outcomes. By fostering collaboration among researchers, clinicians, and patients, Rhode Island Hospital plays a pivotal role in translating scientific discoveries into effective therapies and improving healthcare delivery.

Locations

Providence, Rhode Island, United States

Patients applied

0 patients applied

Trial Officials

W. Curt LaFrance Jr, MD, MPH

Principal Investigator

Brown University Health

Emily Weisbach, MD

Study Chair

Brown University Health

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported